Pathophysiology
HbSS or compound heterozygotes; deoxy-HbS polymers deform erythrocytes, causing microvascular occlusion, chronic haemolysis and nitric oxide depletion.
Sources: NHLBI Sickle Cell 2020; Exa-cel (NEJM 2024;390:1649)
Presentation
Vaso-occlusive pain crises, dactylitis in infants, acute chest syndrome, stroke, splenic sequestration and functional asplenia (encapsulated organism risk), priapism, avascular necrosis, chronic pain.
Diagnosis
Newborn screening (Hb electrophoresis or HPLC); confirms HbS. Peripheral smear: sickle cells, Howell-Jolly bodies, target cells.
Management
Hydroxyurea (increases HbF), voxelotor (Hb polymerisation inhibitor), crizanlizumab (P-selectin), l-glutamine; transfusion for stroke/ACS; chronic transfusion + hydroxyurea for stroke prevention; allogeneic HSCT curative; gene therapies (exa-cel, lovo-cel) approved.




